Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $230,167 | 106 | 45.1% |
| Consulting Fee | $203,759 | 70 | 39.9% |
| Travel and Lodging | $55,890 | 142 | 10.9% |
| Food and Beverage | $11,369 | 236 | 2.2% |
| Honoraria | $9,250 | 6 | 1.8% |
| Education | $232.44 | 8 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $351,359 | 336 | $0 (2024) |
| GlaxoSmithKline, LLC. | $45,480 | 21 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $37,667 | 58 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $17,614 | 20 | $0 (2023) |
| AKEBIA THERAPEUTICS INC | $16,334 | 7 | $0 (2022) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $11,046 | 5 | $0 (2021) |
| Otsuka Pharmaceutical Co., Ltd. | $7,758 | 13 | $0 (2018) |
| AstraZeneca UK Limited | $6,250 | 2 | $0 (2020) |
| Travere Therapeutics, Inc. | $5,505 | 9 | $0 (2023) |
| PFIZER INC. | $4,568 | 9 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,667 | 16 | AstraZeneca Pharmaceuticals LP ($8,708) |
| 2023 | $39,697 | 42 | GlaxoSmithKline, LLC. ($26,630) |
| 2022 | $90,000 | 88 | AstraZeneca Pharmaceuticals LP ($44,736) |
| 2021 | $67,511 | 76 | AstraZeneca Pharmaceuticals LP ($51,712) |
| 2020 | $102,367 | 89 | AstraZeneca Pharmaceuticals LP ($85,456) |
| 2019 | $152,881 | 156 | AstraZeneca Pharmaceuticals LP ($141,994) |
| 2018 | $25,589 | 59 | Fresenius USA Marketing, Inc. ($10,124) |
| 2017 | $19,955 | 42 | Fresenius USA Marketing, Inc. ($14,986) |
All Payment Transactions
568 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $48.05 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.84 | General |
| Category: DIABETES | ||||||
| 07/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: Inflammation | ||||||
| 05/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Travel and Lodging | In-kind items and services | $42.02 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/02/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/01/2024 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: NEPHROLOGY | ||||||
| 02/29/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $124.34 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $42.02 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/25/2024 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,925.00 | General |
| Category: NEPHROLOGY | ||||||
| 12/19/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: NEPHROLOGY | ||||||
| 12/08/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: NEPHROLOGY | ||||||
| 12/05/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Travel and Lodging | In-kind items and services | $50.00 | General |
| Category: NEPHROLOGY | ||||||
| 11/16/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Travel and Lodging | In-kind items and services | $901.94 | General |
| Category: NEPHROLOGY | ||||||
| 11/16/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Food and Beverage | In-kind items and services | $101.17 | General |
| Category: NEPHROLOGY | ||||||
| 11/03/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: NEPHROLOGY | ||||||
| 10/17/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: NEPHROLOGY | ||||||
| 09/20/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Travel and Lodging | In-kind items and services | $1,081.44 | General |
| Category: NEPHROLOGY | ||||||
| 09/20/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Food and Beverage | In-kind items and services | $113.40 | General |
| Category: NEPHROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 516 | 1,434 | $278,020 | $105,126 |
| 2022 | 6 | 312 | 772 | $124,428 | $48,930 |
| 2021 | 8 | 393 | 895 | $195,783 | $73,675 |
| 2020 | 9 | 288 | 488 | $123,227 | $40,895 |
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 81 | 532 | $119,700 | $53,747 | 44.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 174 | $31,011 | $17,938 | 57.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 83 | 88 | $46,200 | $12,806 | 27.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 101 | $18,938 | $6,786 | 35.8% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 27 | 67 | $22,613 | $4,017 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $7,194 | $2,972 | 41.3% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2023 | 13 | 30 | $22,455 | $2,555 | 11.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $5,320 | $1,958 | 36.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 92 | 212 | $1,590 | $1,558 | 98.0% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 90 | 200 | $3,000 | $788.00 | 26.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 46 | 245 | $55,125 | $22,113 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 70 | 145 | $25,375 | $15,009 | 59.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 41 | $21,525 | $7,208 | 33.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 14 | 57 | $19,238 | $3,620 | 18.8% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2022 | 70 | 138 | $2,070 | $547.84 | 26.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 71 | 146 | $1,095 | $432.45 | 39.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 70 | 344 | $77,400 | $33,364 | 43.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 61 | 116 | $20,300 | $13,151 | 64.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 64 | 67 | $35,175 | $12,692 | 36.1% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 27 | 102 | $34,425 | $6,985 | 20.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 22 | 22 | $8,800 | $4,442 | 50.5% |
| 90937 | Hemodialysis procedure with repeated evaluations | Facility | 2021 | 16 | 23 | $17,216 | $2,268 | 13.2% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2021 | 67 | 108 | $1,620 | $434.16 | 26.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 66 | 113 | $847.50 | $339.00 | 40.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 47 | 165 | $37,125 | $16,009 | 43.1% |
About Dr. Bruce Spinowitz, M.D
Dr. Bruce Spinowitz, M.D is a Nephrology healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467475962.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Spinowitz, M.D has received a total of $510,667 in payments from pharmaceutical and medical device companies, with $12,667 received in 2024. These payments were reported across 568 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($230,167).
As a Medicare-enrolled provider, Spinowitz has provided services to 1,509 Medicare beneficiaries, totaling 3,589 services with total Medicare billing of $268,626. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Bronx, NY
- Active Since 07/25/2006
- Last Updated 05/14/2024
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1467475962
Products in Payments
- LOKELMA (Drug) $247,366
- Velphoro (Drug) $37,575
- FARXIGA (Drug) $26,669
- JESDUVROQ (Drug) $24,657
- Kerendia (Drug) $13,876
- Non-Covered (Drug) $3,738
- Velophoro (Drug) $1,050
- RETACRIT (Biological) $700.00
- Veltassa (Drug) $345.16
- AURYXIA (Drug) $204.47
- JYNARQUE (Drug) $192.01
- Parsabiv (Biological) $149.65
- Vaprisol (Drug) $132.81
- Parsabiv (Drug) $112.95
- RAYALDEE (Drug) $109.10
- INJECTAFER (Drug) $98.37
- LUPKYNIS (Drug) $86.72
- ULTOMIRIS (Biological) $73.75
- SAMSCA (Drug) $70.14
- XARELTO (Drug) $68.15
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Bronx
Joel Neugarten, Md, MD
Nephrology — Payments: $384,806
Enver Akalin, M.d, M.D
Nephrology — Payments: $76,364
John He, Md, MD
Nephrology — Payments: $24,885
Abdurhman Ahmed, M.d, M.D
Nephrology — Payments: $12,466
Dr. Suman Reddy, Md, MD
Nephrology — Payments: $7,783
Mr. Joseph Bonanno, D.o, D.O
Nephrology — Payments: $7,333